Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Ipamorelin
Beginner tier: 100 mcg, daily · 12w on / 4w off · community consensus
Also known as: NNC 26-0161, Ipamorelin
Raun and colleagues tested ipamorelin at 200 times the effective growth hormone dose and still found zero cortisol or ACTH elevation [1]. That result made it the first selective growth hormone secretagogue. The pentapeptide triggers a clean GH pulse through the ghrelin receptor (GHS-R1a). In swine, it did not raise prolactin or stress hormones [1], and users report little hunger. No human efficacy trial has succeeded yet; the only published Phase 2 RCT missed its endpoint, and a second never posted results. Still, hundreds of r/peptides threads and a 4.5/5 community sentiment score put ipamorelin in the top five most-discussed peptides. Adults looking for GH optimization with the fewest hormonal side effects start here, usually stacked with CJC-1295 (no DAC).
What Is Ipamorelin?
Zero cortisol increase at 200 times the effective GH dose. That single data point from Raun et al. (1998)[1] explains why ipamorelin became the default starter peptide for growth hormone optimization.
Ipamorelin (molecular weight ~711 Da) is a synthetic pentapeptide and selective GHS-R1a agonist. It binds the ghrelin receptor on pituitary somatotroph cells, producing a GH pulse within 15 to 30 minutes of subcutaneous injection. Gobburu and colleagues gave healthy men 15-minute IV infusions and modeled the result (1999)[2]. They measured a 2-hour half-life and one GH peak at about 40 minutes.
The real-world use case is straightforward. Most users inject 100 to 300 mcg subcutaneously, one to three times daily on an empty stomach. Nearly everyone stacks it with CJC-1295 (no DAC), also called Mod GRF 1-29, to hit both GHS-R1a and GHRH receptor pathways simultaneously. That dual-pathway approach produces a GH pulse two to three times larger than either peptide alone. Bedtime dosing is the priority; the fasting window matters because insulin raises somatostatin, which fully blunts the GH response.
Community evidence is strong. Hundreds of r/peptides threads (roughly 95,000 subscribers) consistently report improved sleep within one to two weeks, faster recovery by weeks three to four, and gradual body composition changes over six to twelve weeks. The scientific picture is less complete. The only published human RCT, a Phase 2 trial in 117 adults after bowel resection, missed its key endpoint versus placebo (Beck 2014)[6]. A second, 320-patient Phase 2 trial (NCT01280344) finished in 2014 without posted results or a paper. All efficacy data for anti-aging and body composition applications is community-derived. Preclinical work on bone mineral content (Svensson et al. 2000)[3] and cachexia (2024 ferret model)[4] looks promising but hasn't been replicated in humans.
How Ipamorelin Works
Ipamorelin binds selectively to the growth hormone secretagogue receptor type 1a (GHS-R1a) on anterior pituitary somatotroph cells. This receptor is the same target ghrelin activates. Ipamorelin was developed for selective GH release, and users report far less hunger than on GHRP-6. In mice, ipamorelin raised body fat, and secretagogue treatment raised food intake (Lall et al. 2001)[8].
Once GHS-R1a activates, it triggers intracellular calcium signaling in somatotrophs, prompting GH vesicle release into circulation. In healthy men given 15-minute IV infusions, the GH pulse peaked at about 40 minutes (Gobburu et al. 1999)[2]. That pulse then stimulates hepatic IGF-1 production, the downstream mediator of most growth hormone effects on tissue repair, lipolysis, and protein synthesis.
The selectivity is what sets ipamorelin apart. GHRP-2 and GHRP-6 both activate GHS-R1a but also stimulate ACTH release, cortisol secretion, and prolactin elevation at therapeutic doses. Raun et al. (1998)[1] demonstrated that ipamorelin produced no measurable cortisol or ACTH increase even at doses 200 times above the GH-effective threshold. This means it can be dosed multiple times daily without accumulating stress hormone burden.
The 2-hour half-life [2] allows for a pulsatile dosing pattern that mimics natural GH secretion rhythms rather than creating the sustained tonic GH elevation seen with CJC-1295 (with DAC). Pairing ipamorelin with CJC-1295 (no DAC) hits both the GHS-R1a and GHRH receptor simultaneously, producing a complementary pulse roughly two to three times larger than either alone.
Ipamorelin Benefits
- Ipamorelin benefits center on clean growth hormone optimization with the lowest side-effect burden of any GHRP available.
- No cortisol or prolactin elevation in swine. Raun et al. found no prolactin rise, and no ACTH or cortisol rise even at more than 200 times the GH-releasing dose [1].
- Improved deep sleep quality within one to two weeks of starting, the most consistently first-reported benefit across hundreds of r/peptides threads.
- Exposure rose in step with dose across five IV infusion levels in healthy men, and the half-life held at 2 hours [2].
- Less hunger than GHRP-6, by user reports, which suits fat-loss goals. No human study has measured hunger on it. In mice, it raised body fat (Lall et al. 2001)[8].
- Bone mineral content improvements documented in rodent models at 12-plus weeks of dosing (Svensson et al. 2000; Andersen et al. 2001)[3][5], with the compound also countering glucocorticoid-induced bone loss.
- No receptor desensitization documented with continuous use, unlike hexarelin. The 12-on/4-off cycling protocol is precautionary rather than evidence-based for ipamorelin specifically.
Ipamorelin: Science vs Community Consensus
Mechanism well-established: selective GHS-R1a agonist producing a clean GH pulse without cortisol, ACTH, or prolactin co-activation in swine (Raun et al. 1998)[1].
Read the evidence (key study, limitations)
Human PK-PD used 15-minute IV infusions in healthy men (Gobburu et al. 1999)[2]. It found a ~2h half-life, dose-proportional kinetics and one GH peak at ~40 min. The only published human RCT (Phase 2, postoperative ileus after bowel resection, n=117; Beck 2014)[6] showed no efficacy vs. placebo; a second Phase 2 trial (NCT01280344, n=320, completed 2014) never posted results. Ipamorelin has never passed a positive human efficacy trial. No new human RCTs published 2024–2026; new 2024 animal data [4] supports cachexia application but is preclinical only.
Raun et al. 1998 (PMID 9849822): established ipamorelin as first selective GHS; no cortisol/ACTH elevation even at 200× the effective GH dose. Gobburu et al. 1999 (PMID 10496658): human PK-PD modeling after 15-minute IV infusions in healthy men; 2h half-life, dose-proportional PK, GH peak at ~40 min.
Only published human RCT (Phase 2, postoperative ileus after bowel resection, PMID 25331030) missed its key endpoint; a second Phase 2 trial (NCT01280344) never posted results. No approved clinical indication. All long-term dosing and efficacy data is community-derived. Preclinical findings (bone, fat) not replicated in a human trial. New 2024 cachexia study (PMID 39043357) is ferret model only.
Widely regarded as the safest and most beginner-friendly GHRP.
Read the reports (what users report 5, common issues 5)
"Cleanest GHRP": no cortisol, prolactin, or appetite spike vs. GHRP-2 and GHRP-6. Almost universally stacked with CJC-1295 (no DAC) rather than used solo. Primary uses: GH optimization, sleep quality, body recomposition, recovery.
- No cortisol, prolactin, or appetite increase: safest side-effect profile among all GHRPs
- Improved deep sleep quality within 1–2 weeks (most consistent first-reported effect)
- Faster workout recovery by weeks 3–4
- Gradual lean body composition improvement and fat loss over 6–12 weeks
- No receptor desensitization documented with continuous use (unlike hexarelin)
- Slow onset: visible body composition changes require 6–12 weeks; common expectation mismatch
- Strict 2-hour fasting window before injection: compliance is the most common failure point
- Mild injection-site redness/irritation (transient)
- Transient post-injection headache resolving within hours
- Product quality variable: DAC/no-DAC mislabeling, underdosing, and degradation documented
Science and community agree on GHS-R1a mechanism, selectivity vs. other GHRPs, GH pulse characteristics, and 2h half-life. Community dosing of 100–300 mcg/injection aligns with published PK-PD dose-response data. Key divergence: the only published human RCT (postoperative ileus, Phase 2) failed vs. placebo, while community consistently reports sleep and body composition benefits from off-label use. Community applications differ from the failed clinical indication. Fasting window requirement is mechanistically sound (insulin→somatostatin→blunted GH pulse).
Ipamorelin Dosage Guide
With a 2 mg vial and 2 mL bacteriostatic water, you'll get 1,000 mcg/mL. Each 100 mcg dose is 10 units on an insulin syringe. A 5 mg vial reconstituted with 2 mL gives 2,500 mcg/mL, so 200 mcg is 8 units and 300 mcg is 12 units per injection.
The fasting window is the thing most beginners mess up. You need at least two hours with no food before injection. Insulin triggers somatostatin release, which completely blocks the GH pulse. Eating within that window isn't "suboptimal"; it negates the injection entirely. No food for 30 minutes after, either.
Bedtime dosing is priority number one. It amplifies the natural nocturnal GH pulse. If you're dosing twice daily, the morning shot should be fasted on waking. Space injections at least eight hours apart.
Store lyophilized vials at 2 to 8 degrees Celsius. After reconstitution, keep refrigerated and use within three to four weeks. Toss anything cloudy or with particles floating in it.
If you see zero sleep improvement after two weeks with correct fasting timing, suspect the product before blaming the protocol. Get an IGF-1 lab at week four to confirm the peptide is actually working. Product quality varies significantly.
Cycling Protocol
Cycle to maintain receptor sensitivity. Can also be run 5 days on, 2 off weekly.
Ipamorelin has notably lower desensitization risk than other GHRPs (especially hexarelin) due to GHS-R1a selectivity and absence of ACTH pathway activation. The 12-week on/4-week off cycle is precautionary, not evidence-based specifically for ipamorelin. No published RCT-level data on ipamorelin-specific desensitization or tachyphylaxis in humans. Community experience and analog literature support cycling to maintain pituitary somatotroph sensitivity and natural GH axis rhythm. Some longevity clinics run 5 days on/2 days off weekly cycling as an alternative within longer-duration protocols. Extended continuous use (>16 weeks) has produced community-reported diminishing returns, particularly in sleep improvement.
- Sleep improvement effect diminishing after weeks 10–12 despite continued dosing
- IGF-1 levels plateauing or declining despite adherent protocol
- Post-injection GH-flush sensation weakening (early indicator of blunted pituitary response)
- Recovery benefit plateauing or regressing before expected cycle end
Or use the universal Peptide Calculator for any peptide.
Ipamorelin Protocols by Goal
Expected: Improved sleep quality weeks 1–2; recovery improvement weeks 3–4; modest body composition changes by months 2–3
Monitor: Baseline IGF-1 before starting; recheck at week 6 and week 12. Fasting glucose at baseline.
Who Uses Ipamorelin?
How to Use Ipamorelin
- 1Reconstitute the vial
Pull bacteriostatic water into an insulin syringe (29 to 31 gauge). For a 2 mg vial, add 2 mL BAC water to get 1,000 mcg per mL. For a 5 mg vial, add 2 mL to get 2,500 mcg per mL. Let the water slide down the glass wall of the vial. Never spray directly onto the lyophilized powder. Swirl gently until dissolved.
- 2Calculate your syringe units
At 1,000 mcg/mL (2 mg vial + 2 mL): 100 mcg = 10 units, 200 mcg = 20 units, 300 mcg = 30 units. At 2,500 mcg/mL (5 mg vial + 2 mL): 100 mcg = 4 units, 200 mcg = 8 units, 300 mcg = 12 units.
- 3Confirm fasting
At least two hours since your last meal. No exceptions, the GH pulse is fully blunted by insulin.
- 4Clean the injection site with an alcohol swab
Abdomen (avoiding the navel area) is preferred. Rotate sites with each injection.
- 5Step 5
Pinch the skin, insert the needle at a 45-degree angle, inject slowly, and hold for five seconds before withdrawing.
- 6Step 6
If stacking with CJC-1295 (no DAC), draw both peptides into the same syringe or inject at the same site sequentially. Co-administration at the same time is standard.
- 7No food for 30 minutes post-injection
Store the reconstituted vial in the refrigerator immediately.
Timing: bedtime is the priority injection (30 to 60 minutes before sleep). If dosing twice daily, add an AM fasted injection on waking. If three times daily, add a post-workout fasted injection spaced at least three hours from other doses.
Alternative Routes
No human study has measured intranasal or subcutaneous bioavailability. In male rats, intranasal bioavailability was about 20% (PMID 9879640). No dose conversion is established.
Not used in practice due to low and variable mucosal absorption. No standardized intranasal protocol exists in community or clinical settings. SC injection remains the only practical route.
Ipamorelin Stacking Protocols
Works With
Primary and near-universal stack. GHRP (GHS-R1a via ipamorelin) + GHRH (GHRHR via CJC-1295 no-DAC) activates dual pituitary pathways; community reports describe a larger GH pulse than either alone. Co-injected at same site, same time. The no-DAC form (not with DAC) preserves pulsatile GH release matching ipamorelin's mechanism.
100 mcg CJC-1295 (no DAC) + 200 mcg ipamorelin SC co-injected, 1–2× daily, fasted
Pre-mixed 5mg/5mg blend: same mechanism as separate components combined for convenience. Common in telehealth/clinic prescriptions and some research-grade products.
200–300 mcg total blend SC, 1–2× daily, fasted
Injury recovery stack. GH elevation from ipamorelin complements BPC-157's tissue repair signaling for tendon, ligament, and muscle recovery. Different mechanism: separate injections acceptable (BPC-157 near injury site; ipamorelin systemic SC).
Systemic healing and anti-inflammatory effects combined with GH secretagogue anabolic signaling. Used in injury or post-surgery recovery protocols; both administered SC.
Avoid
Concurrent use of two GHRPs causes receptor competition at GHS-R1a with no additional GH benefit. GHRP-6's intense hunger and ghrelin-pathway activation defeats the primary reason to choose ipamorelin (less hunger than GHRP-6, by user reports). Stack one GHRP only.
Competing GHRPs at the same GHS-R1a receptor: no additive GH benefit documented. GHRP-2 adds cortisol and prolactin co-elevation that ipamorelin specifically avoids. Defeats the rationale for choosing ipamorelin. Choose one GHRP per stack.
DAC version's days-long half-life creates sustained tonic GH stimulation that mismatches ipamorelin's pulsatile mechanism. Suppresses natural nocturnal GH peaks and pituitary pulsatility over time. Use CJC-1295 no-DAC (Mod GRF 1-29) instead.
Combining GH secretagogues with exogenous HGH saturates the GH axis, suppresses endogenous pulsatility, and eliminates the primary rationale for secretagogue use (axis preservation). Dramatically increases IGF-1 overshoot and side-effect risk.
Do not combineHow much does Ipamorelin cost?
Typical price
$4.46 to $6.47 per mg
Middle half of 94 US prices for 10 mg vials · read Oct 31
Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.
Pricing updated 2026-04-09
Ipamorelin Side Effects
The most serious risk with ipamorelin is IGF-1 overshoot. Sustained supraphysiological IGF-1 levels carry a theoretical cancer promotion risk, particularly in anyone with active malignancy or a history of cancer. GH promotes cell proliferation. That's the mechanism behind its benefits and its biggest concern. If IGF-1 climbs above the age-adjusted upper normal range on two consecutive readings, the protocol should stop.
Carpal tunnel symptoms (tingling or numbness in the hands) are the clearest signal that GH levels have gone too high. Community reports flag this primarily at the aggressive tier (300 mcg three times daily). This isn't a "push through it" side effect. Tingling means stop immediately, wait at least four weeks, and restart at a lower dose and frequency if appropriate.
Water retention is common, especially at twice-daily or three-times-daily dosing. Mild puffiness around the face or ankles is the typical presentation. Reducing injection frequency (not dose) is the first adjustment.
Transient headache within 30 to 60 minutes of injection is expected and relates directly to the acute GH pulse. It resolves within hours for most users. Cutting the dose by 25% usually handles persistent headache.
Injection-site reactions (mild redness, irritation) are reported frequently in the first two weeks and tend to resolve with consistent site rotation. Abdomen is the preferred injection location.
Occasional lightheadedness immediately post-injection is reported but typically mild.
Published side effect data in humans is limited. Only one human RCT has been published (Phase 2, 117 adults after bowel resection)[6]. It used intravenous dosing and tracked adverse events, but its endpoints were GI recovery, not the subcutaneous anti-aging use case. A second Phase 2 trial in 320 bowel-resection patients (NCT01280344) finished in 2014 and never posted results. Community side-effect reporting across hundreds of threads is remarkably consistent, which provides reasonable confidence in the profile above, but formal incidence rates don't exist for the off-label application.
GH release antagonizes insulin action. Fasting glucose should be monitored at baseline, week six, and week twelve. Anyone with uncontrolled diabetes or severe insulin resistance should not use ipamorelin. A fasting glucose above 126 mg/dL means discontinuation.
Pregnancy and breastfeeding are contraindicated due to insufficient safety data. GH supplementation can also unmask subclinical hypothyroidism by accelerating T4-to-T3 conversion; thyroid monitoring (TSH, fT3) is recommended at baseline.
When to see a doctor: persistent hand tingling or numbness, significant edema, fasting glucose above 126 mg/dL, any visual changes, or symptoms of intracranial hypertension.
Common Issues & Solutions
No IGF-1 change after 6–8 weeks: most common cause is eating within 2 hours before injection: insulin raises somatostatin and fully blunts the GH pulse. Verify fasting compliance before blaming product quality. Then a batch-specific CoA can rule out underdosing or degradation.
Transient headache within 30–60 min of injection: expected with acute GH release; resolves within hours. Reduce dose by 25% if severe or lasting. Ensure adequate hydration pre-injection.
Water retention or hand tingling: reduce injection frequency first (not dose). Tingling/numbness in hands = early carpal tunnel sign: stop immediately and allow 4+ weeks recovery before restarting at lower dose.
Results much slower than expected: ipamorelin is not an acute performance compound: visible body composition changes require 6–12 weeks minimum. Common error is comparing onset timeline to anabolic steroids. IGF-1 lab confirmation at week 4–6 can confirm the protocol is working before visible changes appear.
Suspected product quality issue: CJC-1295 DAC/no-DAC mislabeling is common in lower-quality products. If stacking and seeing no sleep improvement in week 1–2 despite correct timing, suspect product substitution. A CoA specifying ipamorelin molecular weight (~711 Da) is the only way to confirm identity.
Ask AI about this page
Ask AI for a second opinion on Ipamorelin dosing and side effects
Contraindications
- Active malignancy or history of cancer (GH may promote tumor growth)
- Pregnancy or breastfeeding (insufficient safety data)
- Uncontrolled diabetes or severe insulin resistance
- Intracranial hypertension or active pituitary tumors
- Known hypersensitivity to ipamorelin or any excipients
- Children with closed epiphyseal plates (no benefit; risk of side effects)
Drug Interactions
- Exogenous growth hormone (HGH): concurrent use may cause supraphysiological GH levels and increased side effects
- Glucocorticoids (prednisone, dexamethasone): may blunt GH release and reduce ipamorelin efficacy
- Insulin: combined GH elevation can impair glucose tolerance; monitor blood sugar closely
- Somatostatin analogs (octreotide): directly oppose GH release and will negate ipamorelin effects
- Concurrent use of two GHRPs causes receptor competition at GHS-R1a with no additional GH benefit. GHRP-6's intense hunger and ghrelin-pathway activation defeats the primary reason to choose ipamorelin (less hunger than GHRP-6, by user reports). Stack one GHRP only.
- Competing GHRPs at the same GHS-R1a receptor: no additive GH benefit documented. GHRP-2 adds cortisol and prolactin co-elevation that ipamorelin specifically avoids. Defeats the rationale for choosing ipamorelin. Choose one GHRP per stack.
Product Quality
No GMP requirement applies to "research use only" products. Ipamorelin (MW ~711 Da) is a smaller, simpler peptide than CJC-1295 (~3.4 kDa), making synthesis somewhat more consistent, but quality variance across brands remains significant. Key risks: (1) underdosing: peptide content lower than labeled, reducing efficacy; (2) DAC/no-DAC mislabeling is less of an issue for pure ipamorelin than for CJC blends, but still documented; (3) degradation from improper storage or reconstitution. Independent product testing (Finnrick Analytics) shows purity ranges from ~70% to 99.95% across GHRP brands. Athletes: ipamorelin is on WADA 2026 Prohibited List (S2.2.4: GH Releasing Factors); contamination risk from non-dedicated facilities.
- A credible Certificate of Analysis (CoA) is batch-specific, from a named third-party lab, with a certificate number: a generic in-house document is not
- Ipamorelin MW ~711 Da; the CoA should confirm this MW if blending or combined vial concerns exist
- If no sleep improvement after 2 weeks at correct fasting timing, suspect underdosed or degraded product before increasing dose: get an IGF-1 lab at week 4 to confirm
- Store lyophilized vials at 2–8°C; use reconstituted vials within 3–4 weeks (refrigerated at 2–8°C); discard if cloudy or particulate matter present
- Athletes subject to WADA testing should not use ipamorelin: prohibited S2.2.4, detectable via urine immunoassay
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| IGF-1 | Baseline before starting; repeat at week 6 and week 12 | Age-adjusted normal range (not supraphysiological). Flag if consistently above upper limit of normal. |
| IGFBP-3 | Baseline; repeat at week 12 | Age-adjusted normal range |
| Fasting glucose | Baseline; repeat at week 6 and week 12 | <100 mg/dL (normal); 100–125 mg/dL warrants dose reduction and closer monitoring; >126 mg/dL = discontinue |
| Thyroid (TSH, fT3) | Baseline; repeat at week 12 if symptoms emerge | Not listed |
Primary efficacy marker for GH axis activation. Confirms peptide is working and dosing is adequate. Elevated IGF-1 above age-adjusted upper normal indicates dose reduction needed.
Low IGFBP-3 with elevated IGF-1 increases free (bioactive) IGF-1 fraction and downstream cancer signaling risk. IGF-1 alone is insufficient for safe GH axis monitoring.
GH release antagonizes insulin action. Relevant for pre-diabetic or insulin-resistant individuals. Risk is lower than with exogenous HGH but warrants monitoring at higher doses.
GH accelerates T4-to-T3 conversion. Untreated hypothyroidism blunts GH response to ipamorelin. GH supplementation can unmask subclinical hypothyroidism.
Ipamorelin Before and After
Improved sleep quality and deeper sleep onset. Mild injection-site reactions may occur. GH pulses begin but effects are not yet visible.
Noticeable improvements in recovery after exercise. Subtle skin and energy changes. GH and IGF-1 levels begin to rise measurably.
Fat loss becomes apparent, especially around the midsection. Recovery time shortens. Joint and soft-tissue comfort may improve.
Peak benefits in body composition, sleep quality, and recovery. Skin elasticity and tone improvements reported. IGF-1 levels stabilize at elevated baseline.
Receptor sensitivity reset period. Retain most gains from the cycle. GH and IGF-1 gradually return toward pre-cycle baseline over 2-4 weeks.
What to Expect
Weeks 1 to 2: GH pulse augmentation starts with the first injection. In Gobburu's IV infusion study in healthy men [2], GH peaked at about 40 minutes. Sleep quality is the first thing most users notice, often within the first week or two. Deeper sleep onset and more vivid dreams show up consistently across community reports. Mild injection-site redness is common and resolves within hours. Some users report lightheadedness right after the shot. Transient headache in the first 30 to 60 minutes is expected from the acute GH release.
Weeks 3 to 4: IGF-1 becomes measurably raised around week four. Recovery after training improves noticeably, with reduced DOMS and faster bounce-back between sessions. Subtle skin texture and hydration changes start showing up. Some users spot early lean tissue fullness and a bump in daily energy. Mild water retention is possible at twice-daily dosing frequency.
Weeks 5 to 8: Fat loss becomes visible, particularly around the midsection. Recovery windows keep shrinking. Joint and soft-tissue comfort improvements get mentioned frequently in this phase. Skin elasticity changes are noticeable for some users. Rodent studies at this duration showed bone mineral content improvements (Svensson et al. 2000)[3], though human data for this endpoint doesn't exist yet.
Weeks 9 to 12: Peak cycle window. Body composition results are at their best here, with fat loss and muscle fullness peaking. Sleep quality holds steady. Some users report diminishing returns around weeks 10 to 12 and choose to end the cycle early. At the aggressive tier (300 mcg three times daily), mild carpal tunnel-like symptoms are possible. Water retention is the most common nuisance at this stage.
Weeks 13 to 16 (off-cycle): Ipamorelin's short half-life (roughly 2 hours) means it clears the system within 10 to 12 hours of the last injection, no prolonged GH bleed. Pituitary GHS-R1a receptor sensitivity recovers within two to four weeks off. Most users retain a solid portion of their cycle gains for four to six weeks post-cycle. GH and IGF-1 drift back toward pre-cycle baseline gradually. No crash or acute withdrawal has been reported.
Detailed Timeline: Science vs Community
GH pulse augmentation begins with first injection. Human PK-PD (Gobburu 1999, IV infusion) found a GH peak at ~40 min. IGF-1 elevation detectable within days of consistent dosing.
Improved deep sleep quality and more vivid dreams are the first-reported effects, often within 1–2 weeks. Mild injection-site redness resolving within hours. Occasional lightheadedness immediately post-injection.
IGF-1 measurably elevated at week 4 (consistent with GH axis studies). GH promotes anabolic signaling in connective tissue and muscle protein synthesis.
Faster workout recovery, reduced DOMS, subtle improvements in skin texture and hydration. Some users notice early lean tissue fullness and improved energy.
Sustained GH/IGF-1 elevation drives lipolysis and anabolic signaling. Bone mineral content improvements shown at 12+ weeks in rodent models (Svensson et al. 2000, PMID 10828840).
Fat loss begins to show, particularly midsection. Recovery time shortens noticeably. Joint and soft-tissue comfort improvements reported. Skin elasticity improvements noted by some users.
GH and IGF-1 plateau at sustained elevated baseline. Bone mineral content progressively improves with continued dosing per rodent data. No desensitization documented in ipamorelin-specific literature.
Best body composition results of the cycle: fat loss and muscle fullness peak. Sleep quality sustained. Some users experience diminishing returns by weeks 10–12 and end cycle early.
Short half-life (~2h) means ipamorelin clears within 10–12h of last injection (no prolonged GH bleed). Pituitary GHS-R1a receptor sensitivity should recover within 2–4 weeks off.
Most users retain a significant portion of cycle gains for 4–6 weeks post-cycle. GH and IGF-1 gradually return toward pre-cycle baseline over 2–4 weeks. No crash or acute withdrawal reported.
Pharmacokinetics
Source: PK-PD modeling in human volunteers (Pharm Res 1999, PMID 10496658)
Pharmacokinetics: Active Dose Over Time
t½ = ~2 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Ipamorelin Legal?
Ipamorelin is classified as "research use only" in the United States. It has no FDA approval for any clinical indication. Two Phase 2 trials for GI recovery after bowel resection were completed (NCT00672074 and NCT01280344), and neither led to an approved application.
FDA's Pharmacy Compounding Advisory Committee voted against adding ipamorelin to the 503A bulks list on October 29, 2024. Both forms (acetate and free base) drew 0 yes, 12 no and 1 abstention. The vote is advisory, and FDA has not ruled on the listing. Ipamorelin is not on the 503A bulks list (21 CFR 216.23). FDA's Category 2 page (current as of April 22, 2026) still lists ipamorelin acetate for 503B outsourcing facilities, added September 29, 2023. FDA cites immunogenicity risk and a published intravenous gastric-motility study that reported serious adverse events, including death.
Some telehealth and anti-aging clinics prescribe ipamorelin, typically in a combination with CJC-1295.
Athletes: ipamorelin is on the WADA 2026 Prohibited List under S2.2.4 (Growth Hormone Releasing Factors). It is detectable via urine immunoassay. Any athlete subject to anti-doping testing should not use this compound.
This content is for educational and research purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider before using any peptide.
Evidence grade: Phase 2 trial (Peptide Evidence Gap, October 2026)
Who Should Consider Ipamorelin
- Adults seeking natural growth hormone optimization with less hunger than GHRP-6 (user reports)
- Beginners to GH peptide therapy looking for the mildest side-effect profile
- Athletes and active adults focused on recovery and lean body composition
- Older adults with age-related GH decline seeking improved sleep and recovery
- Individuals stacking with CJC-1295 (No DAC) for pulsatile GH release
Related Peptides
What Changed for Ipamorelin
- Evidence
Corrected Oct 15, 2026: ipamorelin's only published human RCT is Beck 2014; a second, 320-patient Phase 2 trial ended without results, per ClinicalTrials.gov.
Before: The only completed human RCT (Phase 2b, postoperative ileus, approximately 100 participants) After: The only published human RCT (Phase 2, 117 adults after bowel resection, PMID 25331030); a second Phase 2 trial (NCT01280344, 320 patients) finished in 2014 without posted results
What this does not mean: Both trials gave ipamorelin intravenously after bowel surgery; neither tested subcutaneous use. Dose tiers on this page are unchanged.
Source: ClinicalTrials.gov NCT01280344, Phase 2 dose-finding trial of ipamorelin vs. placebo for GI recovery after bowel resection (320 enrolled, completed May 2014, no results posted; last update posted Apr 13, 2017) (opens in a new tab) · Saved copy
Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations
References
- [1]Ipamorelin, the first selective growth hormone secretagogue (Eur J Endocrinol 1998) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers (Pharm Res 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]The GH secretagogues ipamorelin and GHRP-6 increase bone mineral content in adult female rats (J Endocrinol 2000) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets (Lu et al., Physiol Behav 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]The GH secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats (Growth Horm IGF Res 2001) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (Beck et al., Int J Colorectal Dis 2014) (opens in a new tab)(n=117)PubMed (opens in a new tab)PubMed
- [7]Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption (Johansen et al., Xenobiotica 1998) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [8]Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues (Lall et al., Biochem Biophys Res Commun 2001) (opens in a new tab)PubMed (opens in a new tab)PubMed
Related Resources
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Ipamorelin?
Hot. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 5. Community mentions on Reddit: Hundreds of threads (top 5 on r/peptides). Open r/peptides (opens in a new tab).
48 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.
